<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748956</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 05-0986</org_study_id>
    <secondary_id>PT050986</secondary_id>
    <nct_id>NCT00748956</nct_id>
  </id_info>
  <brief_title>Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers</brief_title>
  <acronym>NPY</acronym>
  <official_title>Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dennis Charney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is growing evidence that neuropeptides act as neuronal messengers in the brain and have&#xD;
      diverse functions that may include the regulation of mood and behavior. For example,&#xD;
      neuropeptide Y (NPY) is thought to play a role in the adaptive stress response. The&#xD;
      therapeutic application of neuropeptides for psychiatric disorders has been limited by&#xD;
      difficult and unreliable penetration of the blood-brain barrier (BBB). However, recent data&#xD;
      suggest that intranasal administration may provide a means of effectively delivering some of&#xD;
      these neuropeptides to the brain. Thus far it is unclear if this is the case for NPY. The&#xD;
      aims of this project are:&#xD;
&#xD;
        1. To evaluate, in 15 healthy male volunteers aged 25-45, the effect of intranasal NPY&#xD;
           administration (0, 50 and 100 nmol) on its levels in cerebrospinal fluid (CSF), measured&#xD;
           by means of lumbar puncture using an intraspinal catheter between L4 and L5, and in&#xD;
           plasma, measured using an intravenous catheter in the forearm. One of the three&#xD;
           treatments will be administered to each participant in a double-blind fashion. The 0&#xD;
           nmol condition will serve as the placebo control.&#xD;
&#xD;
        2. To test the effect of intranasal NPY administration on mood and anxiety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is growing evidence that neuropeptides, including neuropeptide Y (NPY), act as neuronal&#xD;
      messengers in the brain and have diverse neurobehavioral functions. Their therapeutic&#xD;
      application for psychiatric disorders has been limited, however, by difficult and unreliable&#xD;
      penetration of the blood-brain barrier (BBB). The BBB has prevented the use of many&#xD;
      therapeutic agents for treating central nervous system (CNS) disorders. Several molecules&#xD;
      have successfully been administered through intranasal delivery, however, thanks to the&#xD;
      unique connection that the nerves involved in sensing odors and chemicals provide between the&#xD;
      CNS and its environment.&#xD;
&#xD;
      NPY, the most abundant peptide in the mammalian brain, is co-localized with norepinephrine in&#xD;
      sympathetic nerve fibers and has been of longstanding interest to our research group (Morgan&#xD;
      et al., 2002; Morgan et al., 2003; Morgan et al., 2001; Morgan et al., 2000; Rasmusson et&#xD;
      al., 2000; Rasmusson et al., 1998) because of its potential role in modulating mood and&#xD;
      anxiety. NPY has been implicated as factor in the adaptive stress response (Thorsell et al.,&#xD;
      1999), and has been shown to impact the consolidation of fear-related memories after shock&#xD;
      (Flood et al., 1989). Clinically, lower plasma NPY levels have been correlated with greater&#xD;
      psychological distress, increased symptoms of dissociation, and poorer performance among&#xD;
      active duty military personnel. Acute stress in humans has been found to elicit NPY release,&#xD;
      in a manner parallel to the changes in cortisol and norepinephrine that are usually seen,&#xD;
      with a blunting of the plasma NPY response in response to yohimbine (Morgan et al., 2002).&#xD;
      Baseline NPY levels in combat veterans with PTSD are reduced compared to healthy&#xD;
      non-traumatized individuals (Rasmusson et al., 2000). Another study found that repeated&#xD;
      exposure to traumatic stress, rather than the presence of PTSD or PTSD-type symptoms, is&#xD;
      associated with a reduction in baseline plasma NPY (Morgan et al., 2003). A recent report&#xD;
      found deceased CSF concentrations of NPY in patients with treatment resistant unipolar major&#xD;
      depression (Heilig et al 2004). In summary, there has been suggestion from studies in&#xD;
      patients with anxiety and mood disorders as well as healthy volunteers of an abnormal&#xD;
      regulation of this peptide.&#xD;
&#xD;
      In this study, we will evaluate intranasal administration of NPY in healthy male volunteers&#xD;
      ages 25-45 using a specialized delivery device. Pending the initial feasibility and&#xD;
      tolerability in healthy volunteers, future protocols will examine the effect of intranasal&#xD;
      NPY administration in patients with disorders such as PTSD, major depression, panic disorder,&#xD;
      and social anxiety disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of NPY in CSF</measure>
    <time_frame>on study day 2</time_frame>
    <description>Levels of Neuropeptide Y in the cerebrospinal fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systematic Assessment of Treatment-Emergent Effects (SAFTEE)</measure>
    <time_frame>on study day 2</time_frame>
    <description>Number of participants with serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite Scale</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in 2 hours post intranasal administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-sleep Questionnaire</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms (QIDS)</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in 2 hours post intranasal administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood States (POMS)</measure>
    <time_frame>on study day 2</time_frame>
    <description>measure in 2 hours post intranasal administration and on the next morning</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Mood Disorder</condition>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Low dose NPY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose, Receive 50 nmol dose of NPY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose NPY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose, Receive 100 nmol dose of NPY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose NPY</intervention_name>
    <description>50nmol, administered intranasally</description>
    <arm_group_label>Low dose NPY</arm_group_label>
    <other_name>Neuropeptide Y</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose NPY</intervention_name>
    <description>100nmol administered intranasally</description>
    <arm_group_label>High dose NPY</arm_group_label>
    <other_name>Neuropeptide Y</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator (0nmol)) administered intranasally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged 25-45.&#xD;
&#xD;
          -  No history of Axis I disorder as defined in the DSM-IV other than past nicotine abuse&#xD;
             or dependence or adjustment disorder.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nicotine or caffeine abuse or dependence within the preceding 3 months.&#xD;
&#xD;
          -  History or complaint of nasal disorders or allergies.&#xD;
&#xD;
          -  Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory,&#xD;
             cardiovascular, endocrinologic, neurologic, immunologic, or hematologic.&#xD;
&#xD;
          -  Significant obesity (BMI &gt; 30), scoliosis, spinal stenosis or a history of lumbosacral&#xD;
             laminectomy.&#xD;
&#xD;
          -  Clinically significant abnormal findings of laboratory parameters, physical&#xD;
             examination, or ECG.&#xD;
&#xD;
          -  Current use of any medications that have effects on CNS function.&#xD;
&#xD;
          -  Prior sinonasal surgery, or significant nasal polyps as determined by nasal endoscopy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Feder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Charney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Morgan CA 3rd, Rasmusson AM, Winters B, Hauger RL, Morgan J, Hazlett G, Southwick S. Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biol Psychiatry. 2003 Nov 15;54(10):1087-91.</citation>
    <PMID>14625151</PMID>
  </reference>
  <reference>
    <citation>Morgan CA 3rd, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry. 2000 May 15;47(10):902-9.</citation>
    <PMID>10807963</PMID>
  </reference>
  <reference>
    <citation>Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry. 2000 Mar 15;47(6):526-39.</citation>
    <PMID>10715359</PMID>
  </reference>
  <reference>
    <citation>Rasmusson AM, Southwick SM, Hauger RL, Charney DS. Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Neuropsychopharmacology. 1998 Jul;19(1):95-8.</citation>
    <PMID>9608581</PMID>
  </reference>
  <reference>
    <citation>Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport. 1999 Sep 29;10(14):3003-7.</citation>
    <PMID>10549813</PMID>
  </reference>
  <reference>
    <citation>Flood JF, Baker ML, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res. 1989 Nov 27;503(1):73-82.</citation>
    <PMID>2611661</PMID>
  </reference>
  <reference>
    <citation>Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004 Aug;38(4):213-24. Review.</citation>
    <PMID>15337373</PMID>
  </reference>
  <reference>
    <citation>Eaton K, Sallee FR, Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem. 2007;7(17):1645-59. Review.</citation>
    <PMID>17979774</PMID>
  </reference>
  <reference>
    <citation>Nikisch G, Agren H, Eap CB, Czernik A, Baumann P, Math√© AA. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol. 2005 Sep;8(3):403-10. Epub 2005 Mar 23.</citation>
    <PMID>15784158</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>April 12, 2017</results_first_submitted>
  <results_first_submitted_qc>April 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Dennis Charney</investigator_full_name>
    <investigator_title>Dean</investigator_title>
  </responsible_party>
  <keyword>Mood Disorder</keyword>
  <keyword>Anxiety Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose NPY</title>
          <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
        </group>
        <group group_id="P2">
          <title>High Dose NPY</title>
          <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose NPY</title>
          <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
        </group>
        <group group_id="B2">
          <title>High Dose NPY</title>
          <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Levels of NPY in CSF</title>
        <description>Levels of Neuropeptide Y in the cerebrospinal fluid</description>
        <time_frame>on study day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose NPY</title>
            <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
          </group>
          <group group_id="O2">
            <title>High Dose NPY</title>
            <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of NPY in CSF</title>
          <description>Levels of Neuropeptide Y in the cerebrospinal fluid</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="329.4" spread="119.9"/>
                    <measurement group_id="O3" value="351.0" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systematic Assessment of Treatment-Emergent Effects (SAFTEE)</title>
        <description>Number of participants with serious adverse events</description>
        <time_frame>on study day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose NPY</title>
            <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
          </group>
          <group group_id="O2">
            <title>High Dose NPY</title>
            <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Systematic Assessment of Treatment-Emergent Effects (SAFTEE)</title>
          <description>Number of participants with serious adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Appetite Scale</title>
        <description>measure in 2 hours post intranasal administration</description>
        <time_frame>on study day 2</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose NPY</title>
            <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
          </group>
          <group group_id="O2">
            <title>High Dose NPY</title>
            <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Appetite Scale</title>
          <description>measure in 2 hours post intranasal administration</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-sleep Questionnaire</title>
        <description>measure in the morning</description>
        <time_frame>on study day 2</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose NPY</title>
            <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
          </group>
          <group group_id="O2">
            <title>High Dose NPY</title>
            <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Post-sleep Questionnaire</title>
          <description>measure in the morning</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptoms (QIDS)</title>
        <description>measure in 2 hours post intranasal administration</description>
        <time_frame>on study day 2</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose NPY</title>
            <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
          </group>
          <group group_id="O2">
            <title>High Dose NPY</title>
            <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptoms (QIDS)</title>
          <description>measure in 2 hours post intranasal administration</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Profile of Mood States (POMS)</title>
        <description>measure in 2 hours post intranasal administration and on the next morning</description>
        <time_frame>on study day 2</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose NPY</title>
            <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
          </group>
          <group group_id="O2">
            <title>High Dose NPY</title>
            <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Mood States (POMS)</title>
          <description>measure in 2 hours post intranasal administration and on the next morning</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low Dose NPY</title>
          <description>Low dose, Receive 50 nmol dose of NPY&#xD;
Low dose NPY: 50nmol, administered intranasally</description>
        </group>
        <group group_id="E2">
          <title>High Dose NPY</title>
          <description>High Dose, Receive 100 nmol dose of NPY&#xD;
High dose NPY: 100nmol administered intranasally</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo comparator&#xD;
Placebo: placebo comparator (0nmol)) administered intranasally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache and Nausea</sub_title>
                <description>ER evaluation for headache and nausea</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache requiring hospitalization</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Adriana Feder</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-659-9145</phone>
      <email>adriana.feder@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

